Private company M&A activity is up. Is your company prepared? Find out in 2 charts.

Global M&A hit a historic milestone in Q1 2026. According to PitchBook, “total deal value reaching an estimated $1.6 trillion—a new quarterly record—up 50.6% YoY despite a backdrop of trade policy uncertainty, geopolitical tension, and AI-driven disruption risk.” North America led the way, and “liquidity remains abundant with buyers and sellers finding terms.” With M&A […]

Internships Are Harder to Land Than Ever. Do You Know Your Worth?

In a recent Wall Street Journal Article published last month, they touched on how “internships are more crucial than ever – and even harder to find.” Internship postings are down 16% this year, according to early-career job platform Handshake. Competition is up sharply — the average internship posting drew 109 applicants during the 2024–25 academic […]

Investment Firm Compensation: Why AUM Alone Isn’t Enough

We just wrapped an investment firm consulting project where we looked at the firm’s compensation by both total AUM and size of most recent fund. We found the data to be interesting, so we’re sharing some of the analysis with you in this month’s digest. One of the most influential ways to customize investment firm compensation is […]

The State of Compensation for US Private Biotech Companies

According to PitchBook, “Biopharma companies’ willingness to go public appears to be making a tentative reversal after a long drought…The real drive behind this resurgence, according to investors, is the M&A market.” We looked at our YoY biotech compensation data and used a preview of data from our upcoming US Private Biotech Compensation Report to see […]

The Founder’s Guide to Talent, Capital & Compensation

A strong startup compensation strategy isn’t just a financing exercise — it’s how founders attract the leaders who turn science into value. In this webinar, J. Thelander Consulting founder and CEO Jody Thelander was joined by Chris Garabedian, Joanna & Ellen of JM Search, who co-lead the firm’s biopharma practice, to discuss how founders, boards, […]